Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

FemSeven Sequi, 50 micrograms/10 micrograms/24 hours, transdermal patch

2. Qualitative And Quantitative Composition

Phase 1:

Each patch contains 1.5 mg of estradiol hemihydrate in a patch size of 15 cm2, releasing 50 micrograms of estradiol per 24 hours.

Phase 2:

Each patch contains 1.5 mg of estradiol hemihydrate and 1.5 mg of levonorgestrel in a patch size of 15 cm2, releasing 50 micrograms of estradiol and 10 micrograms of levonorgestrel per 24 hours.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Transdermal patch

Octagonal, transparent, flexible, rounded-edge transdermal matrix patch located on an oversized removable protective liner.

4. Clinical Particulars

4.1 Therapeutic Indications

Hormone Replacement Therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women.

Experience of treating women older than 65 years is limited.

4.2 Posology And Method Of Administration

For transdermal use.

Apply FemSeven Sequi once a week, i.e. replace each patch every 7 days. FemSeven Sequi is a continuous sequential hormone replacement therapy (HRT) without a treatment-off phase: as one patch is removed, the next is applied immediately.

Each treatment cycle with FemSeven Sequi consists of the successive application of two transdermal patches containing estradiol (phase 1) and then two transdermal patches containing estradiol and levonorgestrel (phase 2).

Accordingly, the following treatment cycle should b

FORTRAL INJECTION 30MG/ML

(Pentazocine, as lactate)

Read all of this leaflet carefully before you are given this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have further questions, please ask your doctor, nurse or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What Fortral is and what it is used for
  • 2. Before you are given Fortral
  • 3. How Fortral is given
  • 4. Possible side effects
  • 5. How Fortral is stored
  • 6. Further information

What Fortral Is And What It Is Used For

The name of your medicine is Fortral Injection 30mg/ml (called Fortral throughout this leaflet). Fortral contains a medicine called pentazocine (as lactate). Pentazocine belongs to a group of medicines called analgesics (painkillers).

Fortral is used to treat moderate to severe pain.

Before You Are Given Fortral

Do not have Fortral and tell your doctor if:

  • You are allergic (hypersensitive) to pentazocine or any of the other ingredients in your medicine (listed in Section 6: Further information). Signs of an allergic reaction include a rash and breathing problems. There can also b

Fleet Ready-to-Use 21.4g / 9.4g Enema

Sodium Dihydrogen Phosphate Dihydrate / Disodium Phosphate Dodecahydrate

Read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you need to use Fleet Ready-to-Use Enema carefully to get the best results from it.

  • Keep this leaflet. You may need to read it again.
  • Ask your pharmacist or doctor if you need more information or advice.
  • You must contact a doctor if your symptoms worsen or do not improve after 14 days.
  • If any side effect gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Information in this leaflet:

  • 1. What Fleet Ready-to-Use Enema is and what it is used for.
  • 2. Before you use Fleet Ready-to-Use Enema.
  • 3. How to use Fleet Ready-to-Use Enema.
  • 4. Possible side effects.
  • 5. How to store Fleet Ready-to-Use Enema.
  • 6. Further information.

What Fleet Ready-To-Use Enema Is And What It Is Used For

Fleet Ready-to-Use Enema is a bowel cleanser that acts by increasing the water content of your stools and in this way helps to relieve constipation and clear the bowel.

It can be used in the relief of occasional constipation and where bowel cleansing is required, such as prior to your endoscopy, bowel surgery or X-ray examination.

Before You Use Fleet Ready-To-Use Enema

Do not use Fleet Ready-to-Use Enema and tell your doctor if you:

  • Are al

1. Name Of The Medicinal Product

Fluconazole 200 mg capsules, hard

2. Qualitative And Quantitative Composition

Each capsule, hard contains 200 mg fluconazole.

Excipient: 202.24 mg lactose/hard capsule

For a full list of excipients, see section 6.1

3. Pharmaceutical Form

Capsules, hard

Size '0' hard gelatin capsule filled with white to off-white powder and imprinted with 'E' on white to off-white opaque cap and '98' on white to off-white opaque body with yellow ink.

4. Clinical Particulars

4.1 Therapeutic Indications

Acute or recurrent vaginal candidiasis when systemic therapy is considered appropriate.

Mucosal candidal infection. These include oropharyngeal, oesophageal, mucocutaneous and non-invasive bronchopulmonary candidiasis and candiduria, in patients with compromised immune function.

Systemic candidiasis in non-neutropenic patients.

Acute cryptococcal meningitis in adults. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with AIDS.

Prophylaxis of deep-seated candida infections (particularly Candida albicans) in patients with neutropenia due to bone marrow transplantation.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Paediatric use

Not all indications are applicable for paediatric patients; see details in section 4.2.

Fluconazole should not be used for tinea captis.

4.2 Posology And Method Of Administration

Oral use, capsules should be swallowed whole, independent of food intake.

The do

1. Name Of The Medicinal Product

Fluorouracil Injection 25 mg/ml, solution for injection

2. Qualitative And Quantitative Composition

One vial of Fluorouracil Injection contains:

2500 mg fluorouracil in 100 ml solution (25 mg/ml)

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for injection

Fluorouracil Injection 25 mg/ml, solution for injection, is a clear, colourless or almost colourless solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Fluorouracil Injection 25 mg/ml, solution for injection, may be used alone or in combination, for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.

4.2 Posology And Method Of Administration

Routes of administration:

Fluorouracil Injection can be given by intravenous injection or intravenous or intra-arterial infusion.

Adults:

Selection of an appropriate dose and treatment regime depends upon the condition of the patient, the type of carcinoma being treated and whether fluorouracil is to be administered alone or in combination with other therapy. Initial treatment should be given in hospital and the total daily dose should not exceed 0.8 – 1 gram. It is customary to calculate the dose in accordance with the patient's actual bodyweight unless there is obesity, oedema or some other form of abnormal fluid retention such as ascites. In this case, ideal weight is used as the basis for calculation.

Reduction of the dose is advisable in patients with any of the following:

1. Name Of The Medicinal Product

Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

2. Qualitative And Quantitative Composition

After reconstitution, 1 ml of Fasturtec concentrate contains 1.5 mg rasburicase.

Fasturtec is a recombinant urate-oxidase enzyme produced by genetically modified Saccharomyces cerevisiae strain. Rasburicase is a tetrameric protein with identical subunits of a molecular mass of about 34 kDa.

1 mg corresponds to 18.2 EAU*.

*One enzyme activity unit (EAU) corresponds to the enzyme activity that converts 1?mol of uric acid into allantoin per minute under the operating conditions described: +30°C±1°C TEA pH8.9 buffer.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder and solvent for concentrate for solution for infusion.

The powder is an entire or broken white to off white pellet.

The solvent is a colourless and clear liquid.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in patients with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.

4.2 Posology And Method Of Administration

Fasturtec should be administered under the supervision of a physician trained in chemotherapy of haematological malignancies.

Fasturtec is to be used immediately prior to and during the initiation of chemotherapy only, as at the present, there is insufficient data to recommend multiple treatment courses.

The recommended dose for Fasturtec is 0.20 mg/kg/day. Fasturtec is administ

1. Name Of The Medicinal Product

Fibro-vein 3.0%, 1.0%, 0.5%, 0.2%

2. Qualitative And Quantitative Composition

Active ingredient

Fibro-vein 3% Sodium Tetradecyl Sulphate BP 3.0% w/v

Fibro-vein 1% Sodium Tetradecyl Sulphate BP 1.0% w/v

Fibro-vein 0.5% Sodium Tetradecyl Sulphate BP 0.5% w/v

Fibro-vein 0.2% Sodium Tetradecyl Sulphate BP 0.2% w/v

For excipients, see 6.1

3. Pharmaceutical Form

Intravenous injection

4. Clinical Particulars

4.1 Therapeutic Indications

Fibro-vein 3%

For the treatment of varicose veins of the leg by injection sclerotherapy.

Fibro-vein 1%

For the treatment of small varicose veins and the larger venules of the leg by injection sclerotherapy.

Fibro-vein 0.5%

For the treatment of minor venules and spider veins (venous flares) of the leg by injection sclerotherapy.

Fibro-vein 0.2%

For the treatment of minor venules and spider veins (venous flares) by injection sclerotherapy.

4.2 Posology And Method Of Administration

Route of administration

For intravenous administration into the lumen of an isolated segment of emptied vein followed by immediate continuous compression.

Recommended doses and dosage schedules.

Adults

Fibro-vein 3%

0.5 to 1.0ml of 3.0% Fibro-vein injected intravenously at each of 4 sites (maximum 4ml).

Fibro-vein 1%

0.25 to 1.0ml of 1.0% Fibro-vein injected intravenously at each of 10 sites (maximum 10ml).

Fibro-vein 0.5%

0.25 to 1.0ml of 0.5% Fibro-vein injected i

1. Name Of The Medicinal Product

Frusol 50mg/5ml Oral Solution

2. Qualitative And Quantitative Composition

Furosemide Ph.Eur 50mg/5ml

3. Pharmaceutical Form

Oral Solution

4. Clinical Particulars

4.1 Therapeutic Indications

Furosemide is indicated in all conditions requiring prompt diuresis, including cardiac, pulmonary, hepatic and renal oedema, peripheral oedema due to mechanical obstruction or venous insufficiency and hypertension.

It is also indicated for the maintenance therapy of mild oedema of any origin.

4.2 Posology And Method Of Administration

This liquid should only be taken orally.

The medication should be administered in the morning to avoid nocturnal diuresis.

Adults: The usual initial daily dose is 40mg. This may be adjusted until an effective dose is achieved.

Children: 1 to 3mg/Kg body weight daily up to a maximum total dose of 40mg/day.

Elderly: In the elderly, Furosemide is generally eliminated more slowly. Dosage should be titrated until the required response is achieved.

4.3 Contraindications

Contra-indicated conditions

See also

Hypersensitivity to furosemide, amiloride, sulphonamides or sulphonamide derivatives, and/or any of the excipients of the product.

 

1. Name Of The Medicinal Product

Full Marks Mousse.

2. Qualitative And Quantitative Composition

Phenothrin 0.5% w/w

3. Pharmaceutical Form

Topical mousse.

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment of head louse infestations.

4.2 Posology And Method Of Administration

Caution: Apply the product in a well ventilated room away from naked flames and lighted objects.

Adults, the elderly and children aged 6 months and above:

For topical external use only.

The source of infestation should be sought and treated.

Family members and close contacts should be inspected and, if found to be infected, treated simultaneously.

Shake the can well and invert to expel the mousse.

For Head Lice:

1. Apply sufficient mousse to dry hair at several points on the scalp; massage into the scalp ensuring no part of the scalp is left uncovered. Pay special attention to the temples and crown of the head. Take care to avoid the eyes.

2. Leave on the head for 30 minutes; do not attempt to dry the hair by artificial means (e.g. electric hair dryers).

3. Wash hair with normal shampoo.

4. While the hair is still wet, comb with an ordinary comb. A fine-toothed louse comb can then be used to remove the dead or dying lice and eggs.

Infants:

Not to be used on infants under 6 months of age except under medical supervision.

4.3 Contraindications

Known sensitivity to phenothrin.

4.4 Special Warnings And Precautions Fo

FOSAMAX 10 mg Tablets

(alendronate sodium)

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
  • It is particularly important to understand the information in section 3. How to Take Fosamax, before taking this medicine.

In this leaflet:

  • 1. What Fosamax is and what it is used for
  • 2. Before you take Fosamax
  • 3. How to take Fosamax
  • 4. Possible side effects
  • 5 How to store Fosamax
  • 6. Further information

What Fosamax is and what it is used for

What is Fosamax?

Fosamax contains a medicine called alendronate. This belongs to a group of medicines called ‘bisphosphonates’. Fosamax prevents loss of bone that occurs in women after they have been through the menopause. It can also prevent loss of bone in men or people taking steroids, such as prednisolone and methylprednisolone.

It has also been shown to help rebuild bone and reduce the risk of spine and hip fractures (broken bones) in women (after their menopause) and in men who have thinning of their bones (osteoporosis).

1. Name Of The Medicinal Product

Froben Tablets 100 mg

2. Qualitative And Quantitative Composition

Froben Tablets 100 mg contain 100 mg Flurbiprofen BP.

3. Pharmaceutical Form

The tablets are sugar-coated and yellow in colour. They may be either unprinted or printed in black with an identifying motif.

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment of rheumatoid disease, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and trauma such as periarthritis, frozen shoulder, bursitis, tendinitis, tenosynovitis, low back pain, sprains and strains.

Froben is also indicated for its analgesic effect in the relief of mild to moderate pain in conditions such as dental pain, post-operative pain, dysmenorrhoea and migraine.

4.2 Posology And Method Of Administration

For oral administration. To be taken preferably with or after food.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see Section 4.4).

Adults:

150 to 200 mg daily in two, three or four divided doses. In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dosage may be increased to 300 mg in divided doses.

For dysmenorrhoea, a dosage of 100 mg may be administered at the start of symptoms followed by 50 or 100 mg given at four- to six-hour intervals. The maximum total daily dosage should not exceed 300 mg.

Children:

Not recommended for use in children under 12 years.

Elderly:

The elderly are at increased risk of the serious consequences of adverse reactions. Alt

What You Should Know About Froben Tablets

(flurbiprofen)

Please read this leaflet carefully before you start to take your tablets. lt provides a summary of the information available on your medicine. lf you have any questions or are not sure about anything, ask your doctor or pharmacist.

The active ingredient in Froben tablets is flurbiprofen. The tablets are yellow and come in two strengths:

Froben 50 mg tablets contain 50 mg of Flurbiprofen BP and are marked “F50” in black.

Froben 100 mg tablets contain 100 mg of Flurbiprofen BP and are marked “F100” in black.

The inactive ingredients in Froben tablets are sucrose, lactose, talc, maize starch, titanium dioxide (E171), povidone, liquid glucose, magnesium stearate, stearic acid, colloidal silicon dioxide, quinoline yellow (E104), sandarac tablet varnish, carnauba wax, shellac, iron oxide, sunset yellow (E110) and sodium benzoate. The tablets may also contain small amounts of soya lecithin and polydimethylsiloxane.

Each pack contains 100 tablets.

Froben belongs to a group of medicines called anti-inflammatory pain killers.

Product licence holder:

Abbott Laboratories Ltd.
Queenborough
Kent
ME11 5EL
UK

Manufactured by:

Rottendorf Pharma SARL
Z.I. No 2
Batterie 10

1. Name Of The Medicinal Product

Ferrous Fumarate 140mg/5ml Oral Suspension

2. Qualitative And Quantitative Composition

Each 5ml of suspension contains 140mg ferrous fumarate.

For excipients, see 6.1.

3. Pharmaceutical Form

Oral Suspension

A smooth brown suspension with an odour of elderberry.

4. Clinical Particulars

4.1 Therapeutic Indications

Prophylaxis and treatment of iron deficiency states.

For prophylaxis during pregnancy, a combination of iron and folic acid is usually recommended.

4.2 Posology And Method Of Administration

Shake the bottle before use.

Adults and the elderly: Two 5ml spoonfuls of syrup twice a day. Dose may be increased to four 5ml spoonfuls twice a day, if required.

Children: Full term infants and young children-half to one 5ml spoonful twice a day.

Premature infants: 0.6ml/kg day to 2.4 ml/kg/day.

Method of administration: Oral

4.3 Contraindications

Known hypersensitivity to any of the ingredients of the product.

Must not be used in anaemia's other than those due to iron deficiency.

Iron preparations are contra-indicated in patients with:

• Paroxysmal nocturnal haemoglobinuria. Haemosiderosis, haemochromatosis.

• In patients with active peptic ulcer, regional enteritis and ulcerative colitis.

• In patients receiving repeated blood transfus

1. Name Of The Medicinal Product

FrisiumTM

2. Qualitative And Quantitative Composition

Clobazam 10 mg.

3. Pharmaceutical Form

Tablet

4. Clinical Particulars

4.1 Therapeutic Indications

Frisium is a 1,5-benzodiazepine indicated for the short-term relief (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short term psychosomatic, organic or psychotic illness. The use of Frisium to treat short-term “mild” anxiety is inappropriate and unsuitable.

Before treatment of anxiety states associated with emotional instability, it must first be determined whether the patient suffers from a depressive disorder requiring adjunctive or different treatment. Indeed, in patients with anxiety associated with depression, Frisium must be used only in conjunction with adequate concomitant treatment. Use of benzodiazepine (such as Frisium) alone, can precipitate suicide in such patients.

In patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for adjunctive, i.e. not for primary treatment.

Frisium may be used as adjunctive therapy in epilepsy.

4.2 Posology And Method Of Administration

Treatment of anxiety

The usual anxiolytic dose for adults and adolescents over 15 years of age is 20-30 mg daily in divided doses or as a single dose given at night. Doses up to 60mg daily have been used in the treatment of adult in-patients with severe anxiety.

The lowest dose that can control symptoms should be used. After improvement of the symptoms, the dose may be reduced.

It should not be

1. Name Of The Medicinal Product

Fluphenazine Decanoate Injection BP 25mg/ml, 0.5ml, 1ml & 2ml.

2. Qualitative And Quantitative Composition

Each 1ml contains Fluphenazine Decanoate BP 25mg.

3. Pharmaceutical Form

Solution for injection.

Clear light yellow sterile solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Fluphenazine decanoate is a long-acting antipsychotic agent. It is intended for use in the management of patients who require prolonged parenteral therapy with a neuroleptic drug, such as patients with schizophrenia and those with paranoid psychoses.

Fluphenazine decanoate should be administered by deep intramuscular injection.

4.2 Posology And Method Of Administration

Fluphenazine decanoate should be given by deep intramuscular injection. It is preferable that patients be stabilised on fluphenazine decanoate therapy in hospital. The onset of action is usually 1 to 3 days and significant effects on psychotic symptoms are usually evident within 2 to 4 days.

Adults:

Patients receiving a depot preparation of fluphenazine for the first time may be given 12.5mg (0.5ml) initially (this dose should be halved for patients over 60 years) by deep I.M. injection into the gluteal region. The subsequent doses and between-dose intervals will depend on the patients' response, most patients being successfully maintained within a dose range of 12.5 to 100mg given at a dose interval of between 2 to 5 weeks.

Patients resuming therapy with a depot preparation of fluphenazine may be given the same dose as they were receiving prior to discontinuation of treatment, although the frequency of injections may need to be increased in the early weeks of treatment until

1. Name Of The Medicinal Product

Ferriprox 100 mg/ml oral solution

2. Qualitative And Quantitative Composition

Each ml of oral solution contains 100 mg deferiprone (25 g deferiprone in 250 ml and 50 g deferiprone in 500 ml).

Excipient:

Each ml of oral solution contains 0.4 mg Sunset Yellow (E110).

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Oral solution.

Clear, reddish orange coloured liquid.

4. Clinical Particulars

4.1 Therapeutic Indications

Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.

4.2 Posology And Method Of Administration

Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.

Posology

Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. Dose per kilogram body weight should be calculated to the nearest 2.5 ml. See table below for recommended doses for body weights at 10 kg increments.

Dose table

To obtain a dose of about 75 mg/kg/day, use the volume of oral solution suggested in the following table for the body weight of the patient. Sample body weights at 10 kg increments are listed.

Body weight

(kg)

1. Name Of The Medicinal Product

Flecainide Acetate 100 mg Tablets

2. Qualitative And Quantitative Composition

Each tablet contains flecainide acetate 100 mg.

For excipients, see 6.1.

3. Pharmaceutical Form

Tablet

White circular, biconvex tablets, 8.5mm in diameter, marked “3M” on one side and “TR100” on the other.

4. Clinical Particulars

4.1 Therapeutic Indications

Flecainide tablets are indicated for::

a) AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways.

b) Paroxysmal atrial fibrillation in patients with disabling symptoms when treatment need has been established and in the absence of left ventricular dysfunction (see 4.4, Special warnings and special precautions for use). Arrhythmias of recent onset will respond more readily.

c) Symptomatic sustained ventricular tachycardia.

d) Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms, where these are resistant to other therapy or when other treatment has not been tolerated.

Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.

Flecainide tablets are for oral administration.

4.2 Posology And Method Of Administration

Adults: Supraventricular arrhythmias: The recommended starting dosage is 50mg twice daily and most patients will be controlled at this dose. If required the dose may be increased to a maximum of 300mg daily.

Ventricular arrhythmias: The recommended starting dosage is 100mg twice daily. The maximum daily dose is 400mg and this is norm

1. Name Of The Medicinal Product

Forceval Capsules

2. Qualitative And Quantitative Composition

Each capsule contains:

Vitamin A (as ?-Carotene) HSE 2,500.0 iu
Vitamin D2 (Ergocalciferol) HSE 400.0 iu
Vitamin B1 (Thiamine) USP 1.2 mg
Vitamin B2 (Riboflavin) BP 1.6 mg
Vitamin B6 (Pyridoxine) BP 2.0 mg
Vitamin B12 (Cyanocobalamin) PhEur 3.0 mcg
Vitamin C (Ascorbic Acid) BP 60.0 mg
Vitamin E (dl-?-Tocopheryl Acetate)

FELDENE (piroxicam) DISPERSIBLE TABLETS

Please read this leaflet

This leaflet tells you about Feldene Dispersible Tablets. Please read it before you start to take your medicine. It will help you. If you do not understand or you want to know more, ask your doctor or pharmacist (chemist). Keep this leaflet, you may want to read it again.

The name of this medicine is Feldene Dispersible Tablets. The active ingredient is piroxicam.

(Pack shot)

What is in your medicine?

Feldene Dispersible Tablets come in two strengths containing either 10mg or 20mg piroxicam. Inactive ingredients: lactose, microcrystalline cellulose, hydroxypropyl cellulose, sodium stearyl fumarate.

The 10mg tablets come in containers of 56. The 20mg tablets come in containers of 28.

Product Licence Holder and Manufacturer

Pfizer Limited
Ramsgate Road
Sandwich
Kent
CT13 9NJ

What type of medicine is Feldene?

Piroxicam is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). This means it will help to relieve pain and reduce swelling affecting joints and muscles.

What is your medicine for?

This medicine is used to relieve some symptoms caused by rheumatoid arthritis, osteoarthritis and ankylosing spondylitis (rheumatism of the spine) such as swelling, stiffness and joint pain. It is also

1. Name Of The Medicinal Product

Fucidin® H cream

2. Qualitative And Quantitative Composition

Fucidin® H cream contains Fusidic acid Ph.Eur.2% and Hydrocortisone acetate Ph.Eur.1%.

3. Pharmaceutical Form

Cream for topical administration

4. Clinical Particulars

4.1 Therapeutic Indications

Fucidin® H cream is indicated in eczema and dermatitis with secondary bacterial infections, including atopic eczema, primary irritant dermatitis and allergic and seborrhoeic dermatitis where the organisms responsible are known to be or believed to be sensitive to fusidic acid.

4.2 Posology And Method Of Administration

Adults and Children:

Uncovered lesions – a small quantity should be applied to the affected area twice daily until a satisfactory response is obtained. A single treatment course should not normally exceed 2 weeks.

Covered lesions - less frequent applications may be adequate.

4.3 Contraindications

Known hypersensitivity to fusidic acid/sodium fusidate, hydrocortisone acetate or any of the excipients.

As with other topical corticosteroid preparations, Fucidin® H cream is contraindicated in the following conditions: Primary skin Infections caused by bacteria, fungi or viruses (such as herpes or varicella), skin manifestations in relation to tuberculosis or syphilis, perioral dermatitis and rosacea.

4.4 Special Warnings And Precautions For Use

Long term continuous topical therapy should be avoided. Adrenal suppression can occur even without occlusion. Atrophic changes may occur on the face and to a lesser degree in other parts of the body, after prolonged treatment with topical steroids. Ca